Director/Senior Director
Braveheart Bio
Director/Senior Director
Braveheart Bio
Develops cardiac myosin inhibitors for HCM
About us:
Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity.
With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area.
The role:
The Director/Senior Director of Clinical Quality will serve as a senior quality leader for Braveheart Bio and will be responsible for clinical quality oversight and for maintaining a state of inspection readiness for our late-stage clinical program in hypertrophic cardiomyopathy (HCM). Reporting to the Vice President, Quality, this individual will establish and execute the clinical oversight framework to support global Phase 3 execution, guide clinical development teams, and prepare the organization for future regulatory submissions and commercialization activities. This leader will partner closely with Clinical Operations, Regulatory, Biometrics, Pharmacovigilance, and external CRO and vendor partners to ensure best-in-class quality oversight across all programs. The Director/Senior Director may also build and lead a small quality team as Braveheart grows. This is a hands-on, strategic, and foundational role for a lean, fast-moving biotech entering late-stage development.
Key responsibilities:
Quality Strategy & Leadership
GCP Quality Oversight
Compliance and Inspection Readiness
GDPR & Data Privacy
Cross-Functional Collaboration
Broad GxP Quality Support (As Needed)
Required experience & skills:
Preferred experience & skills:
Base Salary Range: $200,000 - $290,000
This role is also eligible for a competitive total rewards package, which may include an annual bonus, equity, and a comprehensive benefits offering.
We are an equal opportunity employer.
We are committed to inclusion and diversity, and we do not discriminate on the basis of race, gender, religion, gender, sexual orientation, age, color, marital status, veteran status, disability status, national origin, or any characteristic protected under applicable law.
Braveheart participates in the federal E‑Verify program to confirm employment authorization for all new hires.
To learn more about E-Verify please review this poster.
Develops cardiac myosin inhibitors for HCM
Braveheart Bio develops therapies for hypertrophic cardiomyopathy by in-licensing promising drug candidates and advancing them through late-stage clinical trials. Its lead drug, BHB-1893, is a selective small-molecule cardiac myosin inhibitor licensed from Hengrui Pharma for ex-China rights, designed to reduce contractility in heart cells and improve heart performance. The company differentiates itself by pursuing a best-in-class profile with potential improvements in efficacy, safety, and dosing, supported by a high-profile leadership team and investors. Its goal is to bring an approved, globally accessible therapy for HCM that delivers meaningful clinical benefit.
Explore more opportunities at Braveheart Bio